Affordable Access

Dose escalation with three-dimensional conformal radiotherapy for prostate cancer. Is more dose really better in high-risk patients treated with androgen deprivation?

Authors
Type
Published Article
Journal
Clinical Oncology
0936-6555
Publisher
Elsevier
Publication Date
Volume
18
Issue
8
Pages
600–607
Identifiers
PMID: 17051950
Source
Medline
License
Unknown

Abstract

The present study indicates an independent benefit on biochemical outcome of high-dose 3DCRT for low-, intermediate- and high-risk patients and of long-term AAD in high-risk prostate cancer patients.

Statistics

Seen <100 times